In vivo imaging of oligonucleotide delivery.
RNA interference (RNAi) has rapidly become a powerful tool for drug-target discovery and therapeutics. Cancer is an important application for RNAi therapeutics, since abnormal gene regulation is thought to contribute to the pathogenesis and maintenance of the metastatic phenotype of cancer. Many oncogenic genes present enticing therapeutic target possibilities for RNAi. Small interfering RNA (siRNA) and microRNA (miRNA) are potent and specific examples of RNAi are able to silence tumor-related genes and multiple oncogenic pathways and appear to be a rational approach to inhibit tumor growth. In subsequent in vivo studies, an appropriate animal model must be developed for a better evaluation of gene-silencing effects on tumors. How to evaluate the effect of siRNA and miRNA in an in vivo therapeutic model is also important. Bioluminescence imaging is an optical imaging method that can evaluate RNAi in vivo.
Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, Tokyo, Japan.
Fumitaka
F
Takeshita
Ryou-U
RU
Takahashi
Jun
J
Onodera
Takahiro
T
Ochiya
D000818:Animals; D045744:Cell Line, Tumor; D003952:Diagnostic Imaging / Q000379:methods*; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D035683:MicroRNAs / Q000008:administration & dosage; D009841:Oligonucleotides / Q000008:administration & dosage*; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000008:administration & dosage
D035683:MicroRNAs; D009841:Oligonucleotides; D034741:RNA, Small Interfering